Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Research Development N/A N/A N/A N/A 14.38 million
Income Before Tax N/A N/A N/A N/A -17.22 million
Selling General Administrative N/A N/A N/A N/A 5.73 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A N/A -12.54 million
Operating Income N/A N/A N/A N/A -15.64 million
Income Tax Expense 74000 -730000 -3.26 million -3.26 million -1.96 million
Total Revenue N/A N/A N/A N/A 12.08 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 2.04 million
Net Income From Continuing Operations N/A N/A N/A N/A -15.26 million
Net Income Applicable to Common Shares -25.69 million -24.54 million -32.61 million -32.61 million -15.26 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020 Jan 31 2020
Investments -81000 -1.87 million -1.87 million -693000 -693000
Change to Liabilities N/A N/A 6.2 million 403000 403000
Total Cash Flow from Investing Activities N/A N/A -1.87 million -693000 -693000
Net Borrowings N/A N/A -406000 -524000 -524000
Total Cash Flow from Financial Activities 6.54 million 88.92 million 88.92 million -65000 -65000
Change to Operating Activities N/A N/A 2.54 million -6.51 million -6.51 million
Change in Cash N/A 67.47 million 67.47 million -20.65 million -20.65 million
Total Cash from Operating Activities N/A N/A -19.58 million -19.9 million -19.9 million
Depreciation N/A N/A N/A 946000 946000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 64000 64000
Other Cash Flow from Financing Activities N/A N/A -4.07 million -47000 -47000
Change to Net Income N/A N/A 1.84 million 463000 463000
Capital Expenditures 81000 841000 841000 693000 693000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Total Liabailities N/A N/A N/A N/A 177.98 million
Total Stockholder Equity N/A N/A N/A N/A 487.81 million
Other Current Liabilities 18.31 million 22.22 million N/A N/A N/A
Total Assets N/A N/A N/A N/A 665.79 million
Common Stock 1.07 billion 1.06 billion 1.05 billion N/A 960.45 million
Other Current Assets N/A N/A N/A 1.05 billion N/A
Retained Earnings -598.99 million -573.3 million -548.76 million -548.76 million -516.15 million
Other Liabilities 21.94 million 23.22 million 30.79 million 30.79 million 35.58 million
Other Assets 3.21 million 3.33 million 3.31 million 3.31 million 3.24 million
Cash N/A N/A N/A N/A 60.08 million
Total Current Liabilities 91.04 million 87.7 million N/A N/A 76.69 million
Other Stockholder Equity 52.19 million 48.8 million 46.63 million 46.63 million 43.51 million
Property, Plant & Equipment 10.41 million 10.33 million 10.27 million 10.27 million 9.44 million
Total Current Assets 90.46 million 115.74 million N/A N/A 69.39 million
Long Term Investments N/A N/A N/A N/A 1.77 million
Net Tangible Assets -62.6 million -42.71 million -32.28 million -32.28 million -94.13 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 59.95 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 28.61 million 27.6 million N/A N/A 19.48 million

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-12-1990CALL0 0163.54TRUE00
2025-12-19107.6CALL0 1139.02TRUE00
2025-12-19110CALL0 0116.89TRUE00
2025-12-19120CALL0 096.71TRUE00
2025-12-19133.35CALL0 300TRUE00
2025-12-19140CALL0 00TRUE00
2025-12-19150CALL0 081.88TRUE00
2025-12-19162CALL0 10117.46TRUE00
2025-12-19171.5CALL0 5352.52TRUE00
2025-12-19181CALL1 126778.02FALSE10
2025-12-19195CALL1 27409.1FALSE50
2025-12-19200.3CALL5 2372.18FALSE0.30
2025-12-19210.1CALL0 39111.68FALSE00
2025-12-19220CALL0 0474.11FALSE00
2025-12-19230CALL0 0492.29FALSE00
2025-12-19250CALL0 0524.89FALSE00
2025-12-19300CALL0 0590.7FALSE00
2025-12-1990PUT0 01043.39FALSE00
2025-12-19100PUT0 0923.64FALSE00
2025-12-19110PUT0 0824.39FALSE00
2025-12-19120PUT0 0739.3FALSE00
2025-12-19130PUT0 0664.47FALSE00
2025-12-19141.2PUT0 7345.51FALSE00
2025-12-19150.2PUT2 11487.92FALSE-0.07-0.26
2025-12-19160.45PUT3 2691.07FALSE0.450
2025-12-19172.52PUT0 181208.9FALSE00
2025-12-19180PUT0 0374.12TRUE00
2025-12-19191.85PUT50 187.85TRUE1.850
2025-12-19200PUT0 0102.82TRUE00
2025-12-19210PUT0 094.09TRUE00
2025-12-19220PUT0 091.47TRUE00
2025-12-19230PUT0 072.73TRUE00
2025-12-19250PUT0 00TRUE00
2025-12-19300PUT0 00TRUE00
2026-01-160.50CALL0 200TRUE00
2026-01-1610CALL0 100TRUE00
2026-01-161.50CALL0 00TRUE00
2026-01-1620CALL0 1000TRUE00
2026-01-162.50CALL0 12610TRUE00
2026-01-1630CALL0 0352.76TRUE00
2026-01-1640CALL0 100TRUE00
2026-01-1658CALL0 0218.58TRUE00
2026-01-16610.4CALL0 25166.95TRUE00
2026-01-1678.5CALL0 386142.98TRUE00
2026-01-1687.84CALL0 00TRUE00
2026-01-1690CALL0 00TRUE00
2026-01-16105.8CALL0 1500TRUE00
2026-01-16115.95CALL0 180TRUE00
2026-01-16125.93CALL0 57373.46TRUE00
2026-01-16137.26CALL0 21489.14TRUE00
2026-01-16144.3CALL0 13684.7TRUE00
2026-01-16153.8CALL2 89091.69TRUE3.80
2026-01-16161.5CALL0 84478.28TRUE00
2026-01-16172.35CALL1 83379.29TRUE2.350
2026-01-16182CALL15 80784.91FALSE0.620.45
2026-01-16191.16CALL0 1300122.63FALSE00
2026-01-16201CALL0 1809130.61FALSE00
2026-01-16211.5CALL0 590178.84FALSE00
2026-01-16221CALL0 1663228.02FALSE00
2026-01-16231.1CALL0 127983.22FALSE00
2026-01-16240.55CALL0 2018286.02FALSE00
2026-01-16250.85CALL0 1195131.56FALSE00
2026-01-16300.5CALL0 243332.02FALSE00
2026-01-16350.45CALL0 15360.84FALSE00
2026-01-160.50PUT0 0343.62FALSE00
2026-01-1610PUT0 0236.05FALSE00
2026-01-161.50PUT0 0189.92FALSE00
2026-01-1620PUT0 20161.02FALSE00
2026-01-162.50PUT0 0158.33FALSE00
2026-01-1630PUT0 00FALSE00
2026-01-1640PUT0 0153.53FALSE00
2026-01-1650PUT0 00FALSE00
2026-01-1660PUT0 0986.34FALSE00
2026-01-1670.8PUT0 3793.11FALSE00
2026-01-1681.2PUT0 7675.04FALSE00
2026-01-1690.93PUT0 22589.29FALSE00
2026-01-16101.22PUT0 63521.7FALSE00
2026-01-16112.85PUT0 3465.71FALSE00
2026-01-16121.5PUT0 30219.05FALSE00
2026-01-16132.6PUT0 11375.53FALSE00
2026-01-16140.8PUT0 122249.26FALSE00
2026-01-16151.05PUT0 456190.56FALSE00
2026-01-16162.92PUT0 27153.62FALSE00
2026-01-16171.6PUT8 2487.76FALSE0.050.03
2026-01-16182.25PUT0 22122.85TRUE00
2026-01-16193PUT0 4367.94TRUE00
2026-01-16204PUT0 592.64TRUE00
2026-01-16210PUT0 089.53TRUE00
2026-01-16220PUT0 095.58TRUE00
2026-01-16230PUT0 090.06TRUE00
2026-01-16240PUT0 089.94TRUE00
2026-01-162510.8PUT0 594.36TRUE00
2026-01-16300PUT0 00TRUE00
2026-01-16350PUT0 00TRUE00
2026-04-1730CALL0 0164.32TRUE00
2026-04-1750CALL0 0110.99TRUE00
2026-04-17810.3CALL0 261.47TRUE00
2026-04-1799.75CALL0 462.46TRUE00
2026-04-17105.8CALL0 20873.85TRUE00
2026-04-17110CALL0 075.62TRUE00
2026-04-17126.36CALL0 247108.09TRUE00
2026-04-17135.1CALL0 1978.59TRUE00
2026-04-17144.6CALL0 78154.86TRUE00
2026-04-17153.42CALL0 6479.34TRUE00
2026-04-17163.1CALL0 35680.09TRUE00
2026-04-17173.4CALL0 45079.46TRUE00
2026-04-17183CALL0 56068.14FALSE00
2026-04-17191.95CALL0 52779.74FALSE00
2026-04-17202.15CALL0 126684.23FALSE00
2026-04-17212CALL0 305083.19FALSE00
2026-04-17251.45CALL0 2502105.8FALSE00
2026-04-17300.8CALL0 462184.04FALSE00
2026-04-17350.5CALL0 1054200.16FALSE00
2026-04-1730PUT0 00FALSE00
2026-04-1750PUT0 00FALSE00
2026-04-1780PUT0 0379.57FALSE00
2026-04-1790PUT0 0331.35FALSE00
2026-04-17101.7PUT0 0293.41FALSE00
2026-04-17111.85PUT0 13262.03FALSE00
2026-04-17122.2PUT0 15235.17FALSE00
2026-04-17132.4PUT0 54211.57FALSE00
2026-04-17143.2PUT0 11115.12FALSE00
2026-04-17153.1PUT0 111100.91FALSE00
2026-04-17160PUT0 087.33FALSE00
2026-04-17170PUT0 086.58FALSE00
2026-04-17186PUT0 4080.59TRUE00
2026-04-17195.6PUT0 186.88TRUE00
2026-04-17200PUT0 090.34TRUE00
2026-04-17210PUT0 085.96TRUE00
2026-04-17258PUT0 184.98TRUE00
2026-04-17300PUT0 088.79TRUE00
2026-04-17350PUT0 090.08TRUE00
2026-07-1730CALL0 00TRUE00
2026-07-1750CALL0 00TRUE00
2026-07-17100CALL0 066.27TRUE00
2026-07-17110CALL0 070.92TRUE00
2026-07-17127.1CALL2 069.25TRUE7.10
2026-07-17136.9CALL6 081.15TRUE6.90
2026-07-17146.3CALL8 080TRUE6.30
2026-07-17155.61CALL18 076.1TRUE5.610
2026-07-17165.1CALL29 175.5TRUE5.10
2026-07-17174.8CALL6 10878.28TRUE4.80
2026-07-17184.3CALL6 576.36FALSE4.30
2026-07-17193.9CALL12 075.74FALSE3.90
2026-07-17203.7CALL5 14578.2FALSE0.320.09
2026-07-17213.4CALL4 4078.27FALSE3.40
2026-07-17223.1CALL140 13377.87FALSE0.420.16
2026-07-17252.35CALL430 116376.89FALSE0.250.12
2026-07-1730PUT0 00FALSE00
2026-07-1750PUT0 00FALSE00
2026-07-17100PUT0 0227.73FALSE00
2026-07-17110PUT0 0203.45FALSE00
2026-07-17120PUT0 0113.99FALSE00
2026-07-17130PUT0 0101.42FALSE00
2026-07-17140PUT0 0148.15FALSE00
2026-07-17150PUT0 078.33FALSE00
2026-07-17160PUT0 090FALSE00
2026-07-17170PUT0 088.53FALSE00
2026-07-17180PUT0 089.42TRUE00
2026-07-17190PUT0 060.22TRUE00
2026-07-17200PUT0 089.44TRUE00
2026-07-17210PUT0 086.92TRUE00
2026-07-17220PUT0 085.81TRUE00
2026-07-17250PUT0 086.49TRUE00
2027-01-1530CALL0 070.74TRUE00
2027-01-1550CALL0 00TRUE00
2027-01-1588.5CALL0 260.66TRUE00
2027-01-15106.9CALL0 26661.37TRUE00
2027-01-15120CALL0 068.32TRUE00
2027-01-15130CALL0 00TRUE00
2027-01-15154.6CALL0 2269.02TRUE00
2027-01-15175.9CALL47 46072.66TRUE0.40.07
2027-01-15203.6CALL2 14955.18FALSE-0.9-0.2
2027-01-15224.1CALL0 8075.2FALSE00
2027-01-15252.9CALL0 7371.29FALSE00
2027-01-15272.6CALL39 53464.48FALSE2.60
2027-01-15302.15CALL0 48103.42FALSE00
2027-01-15350CALL0 0112.74FALSE00
2027-01-1530PUT0 00FALSE00
2027-01-1550PUT0 00FALSE00
2027-01-1580PUT0 0222.03FALSE00
2027-01-15102.35PUT0 2157.75FALSE00
2027-01-15120PUT0 0137.99FALSE00
2027-01-15130PUT0 00FALSE00
2027-01-15150PUT0 084.12FALSE00
2027-01-15170PUT0 081.26FALSE00
2027-01-15207.6PUT0 281.99TRUE00
2027-01-15220PUT0 083.28TRUE00
2027-01-15250PUT0 086.79TRUE00
2027-01-15270PUT0 085.92TRUE00
2027-01-15300PUT0 079.98TRUE00
2027-01-15350PUT0 083.39TRUE00
2028-01-2130CALL0 00TRUE00
2028-01-2150CALL0 00TRUE00
2028-01-2189CALL0 253.32TRUE00
2028-01-21109CALL0 560.11TRUE00
2028-01-21128.5CALL0 161.3TRUE00
2028-01-21150CALL0 065.57TRUE00
2028-01-21177.82CALL89 113571.91TRUE1.220.18
2028-01-21205.2CALL0 2067.12FALSE00
2028-01-21225.6CALL0 5367.36FALSE00
2028-01-21254.9CALL0 069.14FALSE00
2028-01-21275.58CALL60 89673.77FALSE0.930.2
2028-01-21304.8CALL2 1771.17FALSE4.80
2028-01-21353.41CALL0 2570.33FALSE00
2028-01-2130PUT0 00FALSE00
2028-01-2150PUT0 00FALSE00
2028-01-2180PUT0 0165.44FALSE00
2028-01-21102.88PUT0 5165.94FALSE00
2028-01-21124PUT0 1869.33FALSE00
2028-01-21156.1PUT0 2082.68FALSE00
2028-01-21170PUT0 085.25FALSE00
2028-01-21209PUT0 1084.34TRUE00
2028-01-212211PUT0 1084.87TRUE00
2028-01-21250PUT0 074.46TRUE00
2028-01-21270PUT0 086.64TRUE00
2028-01-21300PUT0 082.61TRUE00
2028-01-21350PUT0 086.09TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm